BioSpace News Archive

Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a medical technology and digital health company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders, today announced the company will participate in the upcoming Piper Virtual Healthcare Conference.

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; “Idera”) today announced that Daniel Soland will join Idera on January 4, 2021, as Senior Vice President and Chief Operating Officer (COO).

180 Life Sciences Corp., a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, released the following letter to stockholders from its Chief Executive Officer, Dr. James Woody.

The American Cancer Society and Pfizer have approved grants totaling more than $3.7 million in 10 communities focused on reducing racial disparities in care and helping optimize cancer outcomes for Black men and women.

The expansion, which will be operational in early 2022, will increase API manufacturing capacity to meet current customer needs and support growing demand within the industry

- Week 48 (24 Weeks Post-Treatment) Results Presented - 23% of Patients BLOQ or Undetectable HDV RNA at Week 48 - 55% of Patients Improved in Histology Activity Index (HAI) at Week 48

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of a Phase 1 clinical trial to evaluate PTC518 in healthy volunteers. PTC518 was identified from PTC’s splicing platform and is being developed for the treatment of

Biocept, Inc. announces that results from a prospective study using Target Selector™ testing to monitor disease progression in patients with metastatic breast cancer will be featured in a poster presentation at the virtual 2020 San Antonio Breast Cancer Symposium® on December 9, 2020.

Somryst is the only FDA-authorized prescription digital therapeutic for the treatment of chronic insomnia. Pear is launching Somryst via an end-to-end virtual care experience combining virtual doctor visit(s) via telemedicine provider, with PearConnect™, the industry’s first patient service center for prescription digital therapeutics (PDTs).

TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has received approval from the U.S. Food and Drug Administration for its Investigational Device Exemption application for its vascular sealant. The approval is the most recent validation of TISSIUM’s efforts to de